Atlantic Park and GIC completed a €550m investment in CHEPLAPHARM.

Atlantic Park, a private equity fund, and GIC, a sovereign wealth fund, completed a €550m investment in CHEPLAPHARM, an international platform for well-established branded medicines. “Atlantic Park is delighted to support CHEPLAPHARM’s management team as they pursue their growth ambitions. Empowering and further strengthening market leaders like CHEPLAPHARM is a core pillar of Atlantic Park's investment philosophy, and we are excited to bring the relationships and expertise of our partners on General Atlantic's Life Sciences team to bear for the company," Tripp Smith, Atlantic Park Founder and Managing Director.